석기태 교수
전문진료분야
간염, 지방간, 간경변, 간암, 치료내시경, 고주파 열치료
전화 예약
033) 240-5000
기본정보
학력
2008.09 ~ 2010.08연세대학교 의학 박사 1993.03 ~ 1999.02연세대학교 원주캠퍼스 의학 학사 2001.03 ~ 2003.02연세대학교 내과 석사 |
경력
現 한림대학교춘천성심병원 소화기내과 과장 現 한림대학교 의과대학 내과학 교수 2014 ~ 2016Post-Doc Research Scholar, Department of Medicine, Columbia University, NY, USA Toranomon hospital (Tokyo) 단기방문교수 2007 ~ 2009연세대학교 원주세브란스기독병원 연구강사 및 임상조교수 2004 ~ 2006이라크 자이툰 병원 내과과장 1999 ~ 2004연세대학교 원주세브란스기독병원 수련의 및 전공의 |
학회활동
임상초음파학회 평생회원 대한 소화기항암학회 정회원 대한 Helicobacter 및 상부위장관 연구학회 평생회원 대한 내과학회 평생회원 대한 소화기내시경학회 평생회원 대한 소화기학회 정회원 대한 간학회 평생회원 |
수상이력
Marquis Who's Who (2018) Liver Week Best Presentation (2017) 세계인명사전 Marquis Who's Who 2016 등재 Liver Week 대한간학회 GSK 학술논문상 (2016) Liver week 우수발표상 (2012) 최우수발표상 (2014) 장연구학회 우수연제상 (2009) 소화기내시경학회 월봉학술상 대상 (2008) 대한 Helicobacter 및 상부위장관 연구학회 우수상 (2008) |
논문
1. Eom JA, Park IG, Hyun JY, Lee NY, Kwon GH, Yoon SJ, Won SM, Ham YL, Lee KJ, Han SH, Yang DH, Kim DJ, Suk KT. Pharmabiotics, Phocaeicola dorei, ameliorates cholestatic liver fibrosis by alleviating macrophage efferocytosis of neutrophils. Nat Commun. 2026 May 17. doi: 10.1038/s41467-026-73166-1.
4. Vázquez-Castellanos JF, Yoon SJ, Won SM, Raes J, Kwon HC, Si J, Suk KT. Stage-dependent gut microbiome and functional signatures across the liver disease spectrum: an integrative multicohort study. Gut. 2026 Mar 23:gutjnl-2025-337436. doi: 10.1136/gutjnl-2025-337436.
7. Won SM, Joung H, Park IG, Han SH, Ham YL, Han JS, Kwon Y, Kim DJ, Suk KT. The effects of next generation probiotics on metabolic dysfunction-associated steatotic liver disease: a parallel, double-blind, randomized, placebo-controlled trial. J Transl Med. 2025 Dec 9;24(1):61. doi: 10.1186/s12967-025-07478-z.
8. Oh KK, Kwon GH, Eom JA, Lee KJ, Kim DJ, Suk KT. Clinical-data-driven pharmacological framework in liver disease: From liver cirrhosis to hepatocellular carcinoma. Br J Pharmacol. 2026 May;183(9):1920-1938. doi: 10.1111/bph.70286.
9. Oh KK, Kwon GH, Lee KJ, Eom JA, Kim DJ, Suk KT. A roadmap to unveil the mechanism(s) of natural indole-derived molecules against NAFLD-derived HCC via systems pharmacology. Transl Oncol. 2026 Jan;63:102618. doi: 10.1016/j.tranon.2025.102618.
10. Oh KK, Song SH, Park JH, Kim MJ, Kim DJ, Suk KT. A scheme to navigate "biomolecule X" from Platycladi Folium against hepatocellular carcinoma via phytoinformatics. Transl Oncol. 2025 Dec;62:102546. doi: 10.1016/j.tranon.2025.102546
11. Sharma SP, Cha MG, Kwon GH, Song SH, Park JH, Kim MJ, Eom JA, Lee KJ, Yoon SJ, Park H, Won SM, Oh KK, Ham YL, Baik GH, Kim DJ, Suk KT. Phocaeicola plebeius oral treatment improve fibrosis by reversing cirrhosis-related hepatic gene dysregulation. Life Sci. 2025 Nov 15;381:123979. doi: 10.1016/j.lfs.2025.123979.
12. Yoon SJ, Choi J, Won SM, Yu JS, Kim HY, Joung HC, Park IG, Eom JA, Han SH, Lee DY, Suk KT. Probiotic-Derived Strain-Specific Metabolites Ameliorate Metabolic Dysfunction-Associated Steatotic Liver Disease through Modulation of the Gut-Liver Axis. Probiotics Antimicrob Proteins. 2026 Apr;18(3):4353-4366. doi: 10.1007/s12602-025-10761-6.
13. Kim M, Kim SA, Kim JM, Kim HY, Yoon HY, Park SW, Park D, Han JS, Suk KT. Validation of combo ichroma as a reliable concentration-based alternative for AST and ALT measurement in liver disease monitoring. Methods. 2025 Nov;243:66-75. doi: 10.1016/j.ymeth.2025.08.011.
14. Choi J, Choi YR, Jeong MK, Song HH, Yu JS, Song SH, Park JH, Kim MJ, Park H, Ham YL, Han SH, Kim DJ, Lee DY, Suk KT. Phocaeicola dorei ameliorates progression of steatotic liver disease by regulating bile acid, lipid, inflammation and proliferation. Gut Microbes. 2025 Dec;17(1):2539448. doi: 10.1080/19490976.2025.2539448.
15. Yoon SJ, Han SK, Kim TS, Suk KT, Choi DH, Kim YD, Kim MY, Cheon GJ, Baik SK, Kim DJ. Crit Rev Microbiol. 2025 Nov;51(6):1315-1329. doi: 10.1080/1040841X.2025.2501590.
16. Oh KK, Song SH, Park JH, Kim MJ, Kim DJ, Suk KT. A signpost to guide the key therapeutic components of Aralia continentalis Kitag roots in treating T2DM-derived heart attack, and diabetic nephropathy via systems biology concept. Life Sci. 2025 Jul 1;372:123635. doi: 10.1016/j.lfs.2025.123635.
17. Lee SY, Lee SB, Kwon GH, Song SH, Park JH, Kim MJ, Eom JA, Lee KJ, Yoon SJ, Park H, Won SM, Jeong JJ, Oh KK, Ham YL, Baik GH, Kim DJ, Sharma SP, Suk KT. Synbiotic combination of fructooligosaccharides and probiotics ameliorates the metabolic dysfunction-associated steatotic liver disease. J Microbiol. 2025 Feb;63(2):e2411002. doi: 10.71150/jm.2411002.
18. Oh KK, Yoon SJ, Eom JA, Lee KJ, Kwon GH, Kim DJ, Suk KT. The assembled decoders to prepare for "bioactive X″ against progressive deterioration of liver disease: From NAFLD to HCC. Eur J Med Chem. 2025 Apr 15;288:117385. doi: 10.1016/j.ejmech.2025.117385.
19. Sharma SP, Suk KT. Reply to: "Unveiling the distinctive gut microbiota and metabolites in liver cirrhosis and its complications: Novel diagnostic biomarkers" Clin Mol Hepatol. 2024 Oct 15. doi: 10.3350/cmh.2024.0872.
4. Vázquez-Castellanos JF, Yoon SJ, Won SM, Raes J, Kwon HC, Si J, Suk KT. Stage-dependent gut microbiome and functional signatures across the liver disease spectrum: an integrative multicohort study. Gut. 2026 Mar 23:gutjnl-2025-337436. doi: 10.1136/gutjnl-2025-337436.
7. Won SM, Joung H, Park IG, Han SH, Ham YL, Han JS, Kwon Y, Kim DJ, Suk KT. The effects of next generation probiotics on metabolic dysfunction-associated steatotic liver disease: a parallel, double-blind, randomized, placebo-controlled trial. J Transl Med. 2025 Dec 9;24(1):61. doi: 10.1186/s12967-025-07478-z.
8. Oh KK, Kwon GH, Eom JA, Lee KJ, Kim DJ, Suk KT. Clinical-data-driven pharmacological framework in liver disease: From liver cirrhosis to hepatocellular carcinoma. Br J Pharmacol. 2026 May;183(9):1920-1938. doi: 10.1111/bph.70286.
9. Oh KK, Kwon GH, Lee KJ, Eom JA, Kim DJ, Suk KT. A roadmap to unveil the mechanism(s) of natural indole-derived molecules against NAFLD-derived HCC via systems pharmacology. Transl Oncol. 2026 Jan;63:102618. doi: 10.1016/j.tranon.2025.102618.
10. Oh KK, Song SH, Park JH, Kim MJ, Kim DJ, Suk KT. A scheme to navigate "biomolecule X" from Platycladi Folium against hepatocellular carcinoma via phytoinformatics. Transl Oncol. 2025 Dec;62:102546. doi: 10.1016/j.tranon.2025.102546
11. Sharma SP, Cha MG, Kwon GH, Song SH, Park JH, Kim MJ, Eom JA, Lee KJ, Yoon SJ, Park H, Won SM, Oh KK, Ham YL, Baik GH, Kim DJ, Suk KT. Phocaeicola plebeius oral treatment improve fibrosis by reversing cirrhosis-related hepatic gene dysregulation. Life Sci. 2025 Nov 15;381:123979. doi: 10.1016/j.lfs.2025.123979.
12. Yoon SJ, Choi J, Won SM, Yu JS, Kim HY, Joung HC, Park IG, Eom JA, Han SH, Lee DY, Suk KT. Probiotic-Derived Strain-Specific Metabolites Ameliorate Metabolic Dysfunction-Associated Steatotic Liver Disease through Modulation of the Gut-Liver Axis. Probiotics Antimicrob Proteins. 2026 Apr;18(3):4353-4366. doi: 10.1007/s12602-025-10761-6.
13. Kim M, Kim SA, Kim JM, Kim HY, Yoon HY, Park SW, Park D, Han JS, Suk KT. Validation of combo ichroma as a reliable concentration-based alternative for AST and ALT measurement in liver disease monitoring. Methods. 2025 Nov;243:66-75. doi: 10.1016/j.ymeth.2025.08.011.
14. Choi J, Choi YR, Jeong MK, Song HH, Yu JS, Song SH, Park JH, Kim MJ, Park H, Ham YL, Han SH, Kim DJ, Lee DY, Suk KT. Phocaeicola dorei ameliorates progression of steatotic liver disease by regulating bile acid, lipid, inflammation and proliferation. Gut Microbes. 2025 Dec;17(1):2539448. doi: 10.1080/19490976.2025.2539448.
15. Yoon SJ, Han SK, Kim TS, Suk KT, Choi DH, Kim YD, Kim MY, Cheon GJ, Baik SK, Kim DJ. Crit Rev Microbiol. 2025 Nov;51(6):1315-1329. doi: 10.1080/1040841X.2025.2501590.
16. Oh KK, Song SH, Park JH, Kim MJ, Kim DJ, Suk KT. A signpost to guide the key therapeutic components of Aralia continentalis Kitag roots in treating T2DM-derived heart attack, and diabetic nephropathy via systems biology concept. Life Sci. 2025 Jul 1;372:123635. doi: 10.1016/j.lfs.2025.123635.
17. Lee SY, Lee SB, Kwon GH, Song SH, Park JH, Kim MJ, Eom JA, Lee KJ, Yoon SJ, Park H, Won SM, Jeong JJ, Oh KK, Ham YL, Baik GH, Kim DJ, Sharma SP, Suk KT. Synbiotic combination of fructooligosaccharides and probiotics ameliorates the metabolic dysfunction-associated steatotic liver disease. J Microbiol. 2025 Feb;63(2):e2411002. doi: 10.71150/jm.2411002.
18. Oh KK, Yoon SJ, Eom JA, Lee KJ, Kwon GH, Kim DJ, Suk KT. The assembled decoders to prepare for "bioactive X″ against progressive deterioration of liver disease: From NAFLD to HCC. Eur J Med Chem. 2025 Apr 15;288:117385. doi: 10.1016/j.ejmech.2025.117385.
19. Sharma SP, Suk KT. Reply to: "Unveiling the distinctive gut microbiota and metabolites in liver cirrhosis and its complications: Novel diagnostic biomarkers" Clin Mol Hepatol. 2024 Oct 15. doi: 10.3350/cmh.2024.0872.